Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Week's Bonus Content Tempus AI Sold Off After a Beat—But the Rebound Case Is BuildingBy Thomas Hughes. Originally Published: 2/25/2026. 
Key Points - Tempus AI is framed as deeply discounted versus analyst targets, with improving margins and guidance supporting a rebound setup.
- The quarter showed strong reported growth and durable retention, with narrowing losses and an improving profitability trajectory.
- Analyst sentiment and institutional buying are portrayed as supportive, while debt and short interest remain the main risks.
- Special Report: [Sponsorship-Ad-6-Format3]
Tempus AI (NASDAQ: TEM) looks like an attractive buy for tech traders. The company is a leading provider of AI-enabled services and infrastructure for healthcare, and its stock appears positioned for a strong rebound. Trading near 52-week lows in late February, the share price sits more than 45% below analysts' consensus price targets, even as several tailwinds build in its favor. Those tailwinds include recent outperformance, better-than-expected guidance, and internal metrics that point not only to rising client counts but also to an impressive penetration rate. The takeaway for investors is that Tempus is approaching an inflection to profitability, likely before year-end — a catalyst that could help lift the stock back toward prior highs and potentially beyond. For traders focused on AI-enabled healthcare, that makes TEM notable. Tempus AI Delivers Beat-and-Raise Quarter: Shares Fell Tempus AI reported a strong quarter, with revenue up roughly 83% year-over-year. The top line outpaced MarketBeat's consensus by more than 120 basis points, led by a 121% increase in diagnostics, 56% growth in MRD, and 25% growth in Data & Applications. Much of the expansion reflects acquisitions; on an organic basis, revenue growth is closer to 33.5% — still a solid performance. Remaining contract value stayed robust at over $1.1 billion, and net retention exceeded 125%. The margin picture improved meaningfully. Losses narrowed, gross profit rose 94.7%, and adjusted EBITDA turned positive year-over-year, representing a clear improvement from the prior quarter. Notably, the adjusted metric showed a loss of $0.04 but was materially stronger than consensus estimates — a detail reinforced by upbeat guidance. Guidance offers two reasons for upside. First, management expects full-year 2026 revenue of $1.59 billion, about 65 basis points above consensus. Second, the guidance appears conservative, increasing the probability that Tempus will outpace forecasts in upcoming quarters and provide a catalyst for sentiment. 
Analysts Reaffirm Bullish Outlook for Tempus AI Analyst reaction was muted overall, suggesting the results broadly met expectations and required no sweeping rating changes. Two early updates — from BTIG and Morgan Stanley — reaffirmed Buy and Overweight stances, underscoring the generally bullish interpretation of the quarter. Eight of the 14 ratings tracked by MarketBeat are Buy or better, and the consensus is a Moderate Buy. Price targets remain constructive: BTIG lowered its target but to $90, which still sits above consensus, while Morgan Stanley maintained a higher target that implies roughly 75% upside potential this year. Institutional trends are also supportive. MarketBeat data show institutions own about 25% of the stock and have been net buyers since the IPO. Q1 2026 activity marked a record level of accumulation, with net purchases exceeding $500 million — roughly 5% of market cap — and institutions buying more than $3 for every $1 sold. That creates a sizable support base and a meaningful tailwind, with critical technical support near $50 that could act as a launch pad if tested. Tempus Hits Bottom in Early 2026 Despite Risks Key risks for investors remain the company's debt load and short interest. Debt levels are relatively elevated but appear manageable if the profitability inflection unfolds as expected. That would leave short interest as the primary near-term concern. With short interest near 12% and a strong institutional buying trend, short-covering could accelerate a rally if fundamentals continue to improve. Technically, the stock looks close to a bottom. Stochastic indicators suggest an oversold condition while the MACD shows diminishing bearish momentum, setting up the possibility of a bullish momentum swing. The timing and magnitude of that swing may not be immediate; a more pronounced move could require additional catalysts later in the year, such as expanding partnerships, deeper client adoption, regulatory progress, or new AI-enabled product launches.
| 
Post a Comment
Post a Comment